JACOBIO PHARMACEUTICALS CO LTD has a total of 43 patent applications. It decreased the IP activity by 16.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are CHLORION PHARMA INC, BRUNCKO MILAN and LUNDBECK LA JOLLA RESEARCH CENTER INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 9 | |
#2 | Australia | 5 | |
#3 | Canada | 4 | |
#4 | Taiwan | 4 | |
#5 | United States | 4 | |
#6 | EPO (European Patent Office) | 3 | |
#7 | Republic of Korea | 3 | |
#8 | Singapore | 3 | |
#9 | Mexico | 2 | |
#10 | Brazil | 1 | |
#11 | Chile | 1 | |
#12 | China | 1 | |
#13 | Colombia | 1 | |
#14 | Japan | 1 | |
#15 | Philippines | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Special acyclic compounds | |
#5 | Peptides | |
#6 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Gao Panliang | 27 |
#2 | Ma Cunbo | 26 |
#3 | Kang Di | 25 |
#4 | Wu Xinping | 24 |
#5 | Hu Shaojing | 16 |
#6 | Bai Jinlong | 13 |
#7 | Chu Jie | 12 |
#8 | Wen Chunwei | 12 |
#9 | Pei Xiaoyan | 12 |
#10 | Han Huifeng | 12 |
Publication | Filing date | Title |
---|---|---|
WO2021057991A1 | Binding molecule specific for lif and use thereof | |
US2021094919A1 | Kras mutant protein inhibitors | |
US2021040089A1 | Kras mutant protein inhibitors | |
WO2020244606A1 | Binding molecule specific for cd73 and use of binding molecule | |
WO2020063760A1 | Novel heterocyclic derivatives useful as shp2 inhibitors | |
TW202033520A | Fused ring derivatives used as fgfr4 inhibitors | |
AU2019295983A1 | Tricyclic compounds | |
AU2018239542A1 | Novel heterocyclic derivatives useful as SHP2 inhibitors | |
TW201925186A | Novel heterocyclic derivatives useful as shp2 inhibitors | |
WO2018019252A1 | Novel fused pyridine derivatives useful as fak/aurora kinase inhibitors | |
KR20210019607A | Novel heterocyclic derivatives useful as shp2 inhibitors |